TransMedics Group, Inc. TMDX is well-poised for growth in the coming quarters, courtesy of its strength in Organ Care System ...

TransMedics grew sales by 38% during the second quarter and saw its profit margins double compared to last year. Despite this, there may still be room for improvement, according to its CEO.

The FDA clearance for Bridge to Life’s device arrived on schedule with the company’s projected early 2024 timeline. Despite the new competition, TD Cowen maintains a Buy rating on TransMedics with a ...

TransMedics’ NOP (National OCS Program) is revolutionizing organ transplantation, improving outcomes while reducing long-term healthcare costs. Insurance adoption is the key catalyst, with expanding ...

TransMedics' stock is overvalued despite recent revenue growth, with a 25% annual growth rate priced in, while the transplant market grows at 8.5% CAGR. The company faces stiff competition from ...

Transmedics Group ((TMDX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

TransMedics delivered revenue and net income growth of 48% and 111% in its first-quarter earnings. The company continues to see streamlining efficiencies from its nascent logistical network. Solidly ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...